Faculty
Oncology Division
Alphabetical list (active faculty):   
Andrea Wang-Gillam

Andrea Wang-Gillam, MD, PhD

Associate Professor

Department of Medicine

Oncology Division

Molecular Oncology

Research Interests

  • Pancreatic cancer

Contact

  • 314-362-5740 (office)
  • 314-362-7086 (fax)
  • Division of Oncology
    Campus Box 8056
    Washington University
    660 South Euclid Avenue
    St. Louis, MO 63110
  • 11th Floor Mid-Campus Center (office)

Peer-reviewed Articles

  • Phase I Study of Single Agent NIZ985, a Recombinant Heterodimeric IL-15 Agonist, in Adult Patients With Metastatic or Unresectable Solid Tumors
    Conlon K, Watson DC, Waldmann TA, Valentin A, Bergamaschi C, Felber BK, Peer CJ, Figg WD, Potter EL, Roederer M, McNeel DG, Thompson JA, Gupta S, Leidner R, Wang-Gillam A, Parikh NS, Long D, Kurtulus S, Ho Lee L, Chowdhury NR, Bender F, Pavlakis GN
    J Immunother Cancer 2021 Nov;9(11):3388
  • Vorolanib (X-82), an Oral Anti-VEGFR/PDGFR/CSF1R Tyrosine Kinase Inhibitor, With Everolimus in Solid Tumors: Results of a Phase I Study
    Pedersen KS, Grierson PM, Picus J, Lockhart AC, Roth BJ, Liu J, Morton A, Chan E, Huffman J, Liang C, Wang-Gillam A, Tan B
    Invest New Drugs 2021 Oct;39(5):1298-1305
  • Nonoperative Rectal Cancer Management With Short-Course Radiation Followed by Chemotherapy: A Nonrandomized Control Trial
    Kim H, Pedersen K, Olsen JR, Mutch MG, Chin RI, Glasgow SC, Wise PE, Silviera ML, Tan BR, Wang-Gillam A, Lim KH, Suresh R, Amin M, Huang Y, Henke LE, Park H, Ciorba MA, Badiyan S, Parikh PJ, Roach MC, Hunt SR
    Clin Colorectal Cancer 2021 Sep;20(3):e185-e193
  • Retrospective Case Series Analysis of RAF Family Alterations in Pancreatic Cancer: Real-World Outcomes From Targeted and Standard Therapies
    Hendifar A, Blais EM, Wolpin B, Subbiah V, Collisson E, Singh I, Cannon T, Shaw K, Petricoin EF 3rd, Klempner S, Lyons E, Wang-Gillam A, Pishvaian MJ, O'Reilly EM
    JCO Precis Oncol 2021 Aug 25;5:00494
  • Phase I Study of Docetaxel and Temsirolimus in Refractory Solid Tumors
    Amin M, Gao F, Terrero G, Picus J, Wang-Gillam A, Suresh R, Ma C, Tan B, Baggstrom M, Naughton MJ, Trull L, Belanger S, Fracasso PM, Lockhart AC
    Am J Clin Oncol 2021 Sep 1;44(9):443-448
  • Comprehensive Characterization of 536 Patient-Derived Xenograft Models Prioritizes Candidates For Targeted Treatment
    Sun H, Cao S, Mashl RJ, Mo CK, Zaccaria S, Wendl MC, Davies SR, Bailey MH, Primeau TM, Hoog J, Mudd JL, Dean DA 2nd, Patidar R, Chen L, Wyczalkowski MA, Jayasinghe RG, Rodrigues FM, Terekhanova NV, Li Y, Lim KH, Wang-Gillam A, Van Tine BA, Ma CX, Aft R, Fuh KC, Schwarz JK, Zevallos JP, Puram SV, DiPersio JF, Davis-Dusenbery B, Ellis MJ, Lewis MT, Davies MA, Herlyn M, Fang B, Roth JA, Welm AL, Welm BE, Meric-Bernstam F, Chen F, Fields RC, Li S, Govindan R, Doroshow JH, Moscow JA, Evrard YA, Chuang JH, Raphael BJ, Ding L
    NCI PDXNET Consortium

    Nat Commun 2021 Aug 24;12(1):5086
  • Phase 1 Study Combining Alisertib With Nab-Paclitaxel in Patients With Advanced Solid Malignancies
    Lim KH, Opyrchal M, Acharya A, Boice N, Wu N, Gao F, Webster J, Lockhart AC, Waqar SN, Govindan R, Morgensztern D, Picus J, Tan BR, Baggstrom MQ, Maher CA, Wang-Gillam A
    Eur J Cancer 2021 Sep;154:102-110
  • Efficacy of Perioperative Chemotherapy for Resectable Pancreatic Adenocarcinoma: A Phase 2 Randomized Clinical Trial
    Sohal DPS, Duong M, Ahmad SA, Gandhi NS, Beg MS, Wang-Gillam A, Wade JL 3rd, Chiorean EG, Guthrie KA, Lowy AM, Philip PA, Hochster HS
    JAMA Oncol 2021 Mar 1;7(3):421-427
  • Ablative Five-Fraction Stereotactic Body Radiation Therapy for Inoperable Pancreatic Cancer Using Online MR-Guided Adaptation
    Hassanzadeh C, Rudra S, Bommireddy A, Hawkins WG, Wang-Gillam A, Fields RC, Cai B, Park J, Green O, Roach M, Henke L, Kim H
    Adv Radiat Oncol 2020 Jun 25;6(1):100506
  • A Phase I Trial of Temsirolimus and Erlotinib in Patients With Refractory Solid Tumors
    Park H, Williams K, Trikalinos NA, Larson S, Tan B, Waqar S, Suresh R, Morgensztern D, Van Tine BA, Govindan R, Luo J, Lockhart AC, Wang-Gillam A
    Cancer Chemother Pharmacol 2021 Mar;87(3):337-347
  • Surgical Outcome Results From SWOG S1505: A Randomized Clinical Trial of MFOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel for Perioperative Treatment of Resectable Pancreatic Ductal Adenocarcinoma
    Ahmad SA, Duong M, Sohal DPS, Gandhi NS, Beg MS, Wang-Gillam A, Wade JL 3rd, Chiorean EG, Guthrie KA, Lowy AM, Philip PA, Hochster HS
    Ann Surg 2020 Sep 1;272(3):481-486
  • Conservation of Copy Number Profiles During Engraftment and Passaging of Patient-Derived Cancer Xenografts
    Woo XY, Giordano J, Srivastava A, Zhao ZM, Lloyd MW, de Bruijn R, Suh YS, Patidar R, Chen L, Scherer S, Bailey MH, Yang CH, Cortes-Sanchez E, Xi Y, Wang J, Wickramasinghe J, Kossenkov AV, Rebecca VW, Sun H, Mashl RJ, Davies SR, Jeon R, Frech C, Randjelovic J, Rosains J, Galimi F, Bertotti A, Lafferty A, O'Farrell AC, Modave E, Lambrechts D, Ter Brugge P, Serra V, Marangoni E, El Botty R, Kim H, Kim JI, Yang HK, Lee C, Dean DA 2nd, Davis-Dusenbery B, Evrard YA, Doroshow JH, Welm AL, Welm BE, Lewis MT, Fang B, Roth JA, Meric-Bernstam F, Herlyn M, Davies MA, Ding L, Li S, Govindan R, Isella C, Moscow JA, Trusolino L, Byrne AT, Jonkers J, Bult CJ, Medico E, Chuang JH
    PDXNET Consortium (Contributors include: Wang-Gillam A)

    Nat Genet 2021 Jan;53(1):86-99
  • Intratumoral Injection of Clostridium Novyi-NT Spores in Patients With Treatment-Refractory Advanced Solid Tumors
    Janku F, Zhang HH, Pezeshki A, Goel S, Murthy R, Wang-Gillam A, Shepard DR, Helgason T, Masters T, Hong DS, Piha-Paul SA, Karp DD, Klang M, Huang SY, Sakamuri D, Raina A, Torrisi J, Solomon SB, Weissfeld A, Trevino E, DeCrescenzo G, Collins A, Miller M, Salstrom JL, Korn RL, Zhang L, Saha S, Leontovich AA, Tung D, Kreider B, Varterasian M, Khazaie K, Gounder MM
    Clin Cancer Res 2021 Jan 1;27(1):96-106
  • A Phase II Study of Allogeneic GM-CSF-Transfected Pancreatic Tumor Vaccine (GVAX) With Ipilimumab as Maintenance Treatment for Metastatic Pancreatic Cancer
    Wu AA, Bever KM, Ho WJ, Fertig EJ, Niu N, Zheng L, Parkinson RM, Durham JN, Onners B, Ferguson AK, Wilt C, Ko AH, Wang-Gillam A, Laheru DA, Anders RA, Thompson ED, Sugar EA, Jaffee EM, Le DT
    Clin Cancer Res 2020 Oct 1;26(19):5129-5139
  • FOLFIRINOX for the Treatment of Advanced Gastroesophageal Cancers: A Phase 2 Nonrandomized Clinical Trial
    Park H, Jin RU, Wang-Gillam A, Suresh R, Rigden C, Amin M, Tan BR, Pedersen KS, Lim KH, Trikalinos NA, Acharya A, Copsey ML, Navo KA, Morton AE, Gao F, Lockhart AC
    JAMA Oncol 2020 Aug 1;6(8):1231-1240
  • TPL2 Enforces RAS-Induced Inflammatory Signaling and Is Activated by Point Mutations
    Dodhiawala PB, Khurana N, Zhang D, Cheng Y, Li L, Wei Q, Seehra K, Jiang H, Grierson PM, Wang-Gillam A, Lim KH
    J Clin Invest 2020 Sep 1;130(9):4771-4790
  • Safety and Pharmacokinetics of CXCR4 Peptide Antagonist, LY2510924, in Combination With Durvalumab in Advanced Refractory Solid Tumors
    O'Hara MH, Messersmith W, Kindler H, Zhang W, Pitou C, Szpurka AM, Wang D, Peng SB, Vangerow B, Khan AA, Koneru M, Wang-Gillam A
    J Pancreat Cancer 2020 Mar 12;6(1):21-31
  • Phase Ib/II Study Combining Tosedostat With Capecitabine in Patients With Advanced Pancreatic Adenocarcinoma
    Grierson P, Teague A, Suresh R, Lim KH, Amin M, Pedersen K, Tan B, Huffman J, Boice N, Du L, Liu J, Lockhart AC, Wang-Gillam A
    J Gastrointest Oncol 2020 Feb;11(1):61-67
  • Liposomal Irinotecan + 5-FU/LV in Metastatic Pancreatic Cancer: Subgroup Analyses of Patient, Tumor, and Previous Treatment Characteristics in the Pivotal NAPOLI-1 Trial
    Macarulla Mercade T, Chen LT, Li CP, Siveke JT, Cunningham D, Bodoky G, Blanc JF, Lee KH, Dean A, Belanger B, Wang-Gillam A
    Pancreas 2020 Jan;49(1):62-75
  • A Randomized Phase II Trial of Nab-Paclitaxel and Gemcitabine With Tarextumab or Placebo in Patients With Untreated Metastatic Pancreatic Cancer
    Hu ZI, Bendell JC, Bullock A, LoConte NK, Hatoum H, Ritch P, Hool H, Leach JW, Sanchez J, Sohal DPS, Strickler J, Patel R, Wang-Gillam A, Firdaus I, Yu KH, Kapoun AM, Holmgren E, Zhou L, Dupont J, Picozzi V, Sahai V, O'Reilly EM
    Cancer Med 2019 Sep;8(11):5148-5157
  • Phase II Trial of Levocetirizine With Capecitabine and Bevacizumab to Overcome the Resistance of Antiangiogenic Therapies in Refractory Metastatic Colorectal Cancer
    Amin M, Desai M, Trinkaus K, Brown A, Wang-Gillam A, Tan B, Picus J, Sorscher S, Highkin M, Lears K, Lockhart AC
    J Gastrointest Oncol 2019 Jun;10(3):412-420
  • Results From a Phase IIb, Randomized, Multicenter Study of GVAX Pancreas and CRS-207 Compared With Chemotherapy in Adults With Previously Treated Metastatic Pancreatic Adenocarcinoma (ECLIPSE Study)
    Le DT, Picozzi VJ, Ko AH, Wainberg ZA, Kindler H, Wang-Gillam A, Oberstein P, Morse MA, Zeh HJ 3rd, Weekes C, Reid T, Borazanci E, Crocenzi T, LoConte NK, Musher B, Laheru D, Murphy A, Whiting C, Nair N, Enstrom A, Ferber S, Brockstedt DG, Jaffee EM
    Clin Cancer Res 2019 Sep 15;25(18):5493-5502
  • Neoadjuvant FOLFIRINOX in Patients With Borderline Resectable Pancreatic Cancer: A Systematic Review and Patient-Level Meta-Analysis
    Janssen QP, Buettner S, Suker M, Beumer BR, Addeo P, Bachellier P, Bahary N, Bekaii-Saab T, Bali MA, Besselink MG, Boone BA, Chau I, Clarke S, Dillhoff M, El-Rayes BF, Frakes JM, Grose D, Hosein PJ, Jamieson NB, Javed AA, Khan K, Kim KP, Kim SC, Kim SS, Ko AH, Lacy J, Margonis GA, McCarter MD, McKay CJ, Mellon EA, Moorcraft SY, Okada KI, Paniccia A, Parikh PJ, Peters NA, Rabl H, Samra J, Tinchon C, van Tienhoven G, van Veldhuisen E, Wang-Gillam A, Weiss MJ, Wilmink JW, Yamaue H, Homs MYV, van Eijck CHJ, Katz MHG, Koerkamp BG
    J Natl Cancer Inst 2019 May 14; [Epub ahead of print]
  • Pancreas Cancer-Associated Weight Loss
    Hendifar AE, Petzel MQB, Zimmers TA, Denlinger CS, Matrisian LM, Picozzi VJ, Rahib L
    Precision Promise Consortium (Contributors include: Wang-Gillam A)

    Oncologist 2019 May;24(5):691-701
  • Targeting Stroma: A Tale of Caution
    Wang-Gillam A
    J Clin Oncol 2019 May 1;37(13):1041-1043
  • Liposomal Irinotecan and 5-Fluorouracil/Leucovorin in Older Patients With Metastatic Pancreatic Cancer - A Subgroup Analysis of the Pivotal NAPOLI-1 Trial
    Macarulla T, Blanc JF, Wang-Gillam A, Chen LT, Siveke JT, Mirakhur B, Chen J, de Jong FA
    J Geriatr Oncol 2019 May;10(3):427-435
  • NAPOLI-1 Phase 3 Study of Liposomal Irinotecan in Metastatic Pancreatic Cancer: Final Overall Survival Analysis and Characteristics of Long-Term Survivors
    Wang-Gillam A, Hubner RA, Siveke JT, Von Hoff DD, Belanger B, de Jong FA, Mirakhur B, Chen LT
    Eur J Cancer 2019 Feb;108:78-87
  • Quality of Life in Metastatic Pancreatic Cancer Patients Receiving Liposomal Irinotecan Plus 5-Fluorouracil and Leucovorin
    Hubner RA, Cubillo A, Blanc JF, Melisi D, Von Hoff DD, Wang-Gillam A, Chen LT, Becker C, Mamlouk K, Belanger B, Yang Y, de Jong FA, Siveke JT
    Eur J Cancer 2019 Jan;106:24-33
  • Immunogenicity of Influenza Vaccination in Patients With Cancer
    Waqar SN, Boehmer L, Morgensztern D, Wang-Gillam A, Sorscher S, Lawrence S, Gao F, Guebert K, Williams K, Govindan R
    Am J Clin Oncol 2018 Mar;41(3):248-253
  • Survival With Nal-IRI (Liposomal Irinotecan) Plus 5-Fluorouracil and Leucovorin Versus 5-Fluorouracil and Leucovorin in Per-Protocol and Non-Per-Protocol Populations of NAPOLI-1: Expanded Analysis of a Global Phase 3 Trial
    Chen LT, Siveke JT, Wang-Gillam A, Li CP, Bodoky G, Dean AP, Shan YS, Jameson GS, Macarulla T, Lee KH, Cunningham D, Blanc JF, Chiu CF, Schwartsmann G, Braiteh FS, Mamlouk K, Belanger B, de Jong FA, Hubner RA
    Eur J Cancer 2018 Dec;105:71-78
  • Concurrent HER or PI3K Inhibition Potentiates the Antitumor Effect of the ERK Inhibitor Ulixertinib in Preclinical Pancreatic Cancer Models
    Jiang H, Xu M, Li L, Grierson P, Dodhiawala P, Highkin M, Zhang D, Li Q, Wang-Gillam A, Lim KH
    Mol Cancer Ther 2018 Oct;17(10):2144-2155
  • Dynamic Changes During the Treatment of Pancreatic Cancer
    Wolff RA, Wang-Gillam A, Alvarez H, Tiriac H, Engle D, Hou S, Groff AF, San Lucas A, Bernard V, Allenson K, Castillo J, Kim D, Mulu F, Huang J, Stephens B, Wistuba II, Katz M, Varadhachary G, Park Y, Hicks J, Chinnaiyan A, Scampavia L, Spicer T, Gerhardinger C, Maitra A, Tuveson D, Rinn J, Lizee G, Yee C, Levine AJ
    Oncotarget 2018 Feb 13;9(19):14764-14790
  • Utility of Endoscopic Ultrasound in Evaluating Local Recurrence After Surgery for Pancreatic Cancer
    Lang GD, Mullady DK, Early DS, Hollander T, Edmundowicz SA, Murad FM, Strasberg SM, Fields RC, Hawkins WG, Doyle MB, Chapman WC, Wang-Gillam A, Kushnir VM
    Clin Gastroenterol Hepatol 2018 Nov;16(11):1834-1835
  • Tumor-Stroma IL1beta-IRAK4 Feedforward Circuitry Drives Tumor Fibrosis, Chemoresistance, and Poor Prognosis in Pancreatic Cancer
    Zhang D, Li L, Jiang H, Li Q, Wang-Gillam A, Yu J, Head R, Liu J, Ruzinova MB, Lim KH
    Cancer Res 2018 Apr 1;78(7):1700-1712
  • First-In-Class ERK1/2 Inhibitor Ulixertinib (BVD-523) in Patients With MAPK Mutant Advanced Solid Tumors: Results of a Phase I Dose-Escalation and Expansion Study
    Sullivan RJ, Infante JR, Janku F, Wong DJL, Sosman JA, Keedy V, Patel MR, Shapiro GI, Mier JW, Tolcher AW, Wang-Gillam A, Sznol M, Flaherty K, Buchbinder E, Carvajal RD, Varghese AM, Lacouture ME, Ribas A, Patel SP, DeCrescenzo GA, Emery CM, Groover AL, Saha S, Varterasian M, Welsch DJ, Hyman DM, Li BT
    Cancer Discov 2018 Feb;8(2):184-195
  • HALO 202: Randomized Phase II Study of PEGPH20 Plus Nab-Paclitaxel/Gemcitabine Versus Nab-Paclitaxel/Gemcitabine in Patients With Untreated, Metastatic Pancreatic Ductal Adenocarcinoma
    Hingorani SR, Zheng L, Bullock AJ, Seery TE, Harris WP, Sigal DS, Braiteh F, Ritch PS, Zalupski MM, Bahary N, Oberstein PE, Wang-Gillam A, Wu W, Chondros D, Jiang P, Khelifa S, Pu J, Aldrich C, Hendifar AE
    J Clin Oncol 2018 Feb 1;36(4):359-366
  • Digital Ischemia and Necrosis: A Rarely Described Complication of Gemcitabine in Pancreatic Adenocarcinoma
    So E, Crees ZD, Crites D, Wang-Gillam A
    J Pancreat Cancer 2017 Aug 1;3(1):49-52
  • Nanoliposomal Irinotecan in the Clinical Practice Guideline for Metastatic Pancreatic Cancer: Applicability to Clinical Situations
    Wang-Gillam A, Von Hoff D, Siveke J, Hubner R, Belanger B, Pipas JM, Chen LT
    J Clin Oncol 2017 Feb 20;35(6):689-690
  • Pacritinib to Inhibit JAK/STAT Signaling in Refractory Metastatic Colon and Rectal Cancer
    Regenbogen T, Chen L, Trinkaus K, Wang-Gillam A, Tan BR, Amin M, Pedersen KS, Park H, Suresh R, Lim KH, Ratchford E, Brown A, Lockhart AC
    J Gastrointest Oncol 2017 Dec;8(6):985-989
  • A Clinically Feasible Multiplex Proteomic Immunoassay as a Novel Functional Diagnostic for Pancreatic Ductal Adenocarcinoma
    Lim KH, Langley E, Gao F, Luo J, Li L, Meyer G, Kim P, Singh S, Kushnir VM, Early DS, Mullady DK, Edmundowicz SA, Wani S, Murad FM, Cao D, Azar RR, Wang-Gillam A
    Oncotarget 2017 Apr 11;8(15):24250-24261
  • Utility of a Multidisciplinary Tumor Board in the Management of Pancreatic and Upper Gastrointestinal Diseases: An Observational Study
    Brauer DG, Strand MS, Sanford DE, Kushnir VM, Lim KH, Mullady DK, Tan BR Jr, Wang-Gillam A, Morton AE, Ruzinova MB, Parikh PJ, Narra VR, Fowler KJ, Doyle MB, Chapman WC, Strasberg SS, Hawkins WG, Fields RC
    HPB (Oxford) 2017 Feb;19(2):133-139
  • Quality-Adjusted Survival With Combination Nal-IRI+5-FU/LV Vs 5-FU/LV Alone in Metastatic Pancreatic Cancer Patients Previously Treated With Gemcitabine-Based Therapy: A Q-TWiST Analysis
    Pelzer U, Blanc JF, Melisi D, Cubillo A, Von Hoff DD, Wang-Gillam A, Chen LT, Siveke JT, Wan Y, Solem CT, Botteman MF, Yang Y, de Jong FA, Hubner RA
    Br J Cancer 2017 May 9;116(10):1247-1253
  • Effect of Selumetinib and MK-2206 Vs Oxaliplatin and Fluorouracil in Patients With Metastatic Pancreatic Cancer After Prior Therapy: SWOG S1115 Study Randomized Clinical Trial
    Chung V, McDonough S, Philip PA, Cardin D, Wang-Gillam A, Hui L, Tejani MA, Seery TE, Dy IA, Al Baghdadi T, Hendifar AE, Doyle LA, Lowy AM, Guthrie KA, Blanke CD, Hochster HS
    JAMA Oncol 2017 Apr 1;3(4):516-522
  • PET of Poly (ADP-Ribose) Polymerase Activity in Cancer: Preclinical Assessment and First In-Human Studies
    Michel LS, Dyroff S, Brooks FJ, Spayd KJ, Lim S, Engle JT, Phillips S, Tan B, Wang-Gillam A, Bognar C, Chu W, Zhou D, Mach RH, Laforest R, Chen DL
    Radiology 2017 Feb;282(2):453-463
  • Constitutive IRAK4 Activation Underlies Poor Prognosis and Chemoresistance in Pancreatic Ductal Adenocarcinoma
    Zhang D, Li L, Jiang H, Knolhoff BL, Lockhart AC, Wang-Gillam A, DeNardo DG, Ruzinova MB, Lim KH
    Clin Cancer Res 2017 Apr 1;23(7):1748-1759
  • Chemotherapy-Associated Posterior Reversible Encephalopathy Syndrome: A Case Report and Review of the Literature
    How J, Blattner M, Fowler S, Wang-Gillam A, Schindler SE
    Neurologist 2016 Nov;21(6):112-117
  • Racial Disparities in the Outcomes of Patients With Stage IV Pancreatic Adenocarcinoma Are Mediated by Chemotherapy Utilization
    Atkins JJ, Fiala MA, Wang-Gillam A, Wildes TM
    Pancreas 2016 Aug;45(7):e33-e34
  • Targeting Focal Adhesion Kinase Renders Pancreatic Cancers Responsive to Checkpoint Immunotherapy
    Jiang H, Hegde S, Knolhoff BL, Zhu Y, Herndon JM, Meyer MA, Nywening TM, Hawkins WG, Shapiro IM, Weaver DT, Pachter JA, Wang-Gillam A, DeNardo DG
    Nat Med 2016 Aug;22(8):851-60
  • FOLFIRINOX for Locally Advanced Pancreatic Cancer: A Systematic Review and Patient-Level Meta-Analysis
    Suker M, Beumer BR, Sadot E, Marthey L, Faris JE, Mellon EA, El-Rayes BF, Wang-Gillam A, Lacy J, Hosein PJ, Moorcraft SY, Conroy T, Hohla F, Allen P, Taieb J, Hong TS, Shridhar R, Chau I, van Eijck CH, Koerkamp BG
    Lancet Oncol 2016 Jun;17(6):801-810
  • Dickkopf-Related Protein 1 (Dkk1) Regulates the Accumulation and Function of Myeloid Derived Suppressor Cells in Cancer
    D'Amico L, Mahajan S, Capietto AH, Yang Z, Zamani A, Ricci B, Bumpass DB, Meyer M, Su X, Wang-Gillam A, Weilbaecher K, Stewart SA, DeNardo DG, Faccio R
    J Exp Med 2016 May 2;213(5):827-840
  • Targeting Tumour-Associated Macrophages With CCR2 Inhibition in Combination With FOLFIRINOX in Patients With Borderline Resectable and Locally Advanced Pancreatic Cancer: A Single-Centre, Open-Label, Dose-Finding, Non-Randomised, Phase 1b Trial
    Nywening TM, Wang-Gillam A, Sanford DE, Belt BA, Panni RZ, Cusworth BM, Toriola AT, Nieman RK, Worley LA, Yano M, Fowler KJ, Lockhart AC, Suresh R, Tan BR, Lim KH, Fields RC, Strasberg SM, Hawkins WG, DeNardo DG, Goedegebuure SP, Linehan DC
    Lancet Oncol 2016 May;17(5):651-662
  • Long-Term ERK Inhibition in KRAS-Mutant Pancreatic Cancer Is Associated With MYC Degradation and Senescence-Like Growth Suppression
    Hayes TK, Neel NF, Hu C, Gautam P, Chenard M, Long B, Aziz M, Kassner M, Bryant KL, Pierobon M, Marayati R, Kher S, George SD, Xu M, Wang-Gillam A, Samatar AA, Maitra A, Wennerberg K, Petricoin EF 3rd, Yin HH, Nelkin B, Cox AD, Yeh JJ, Der CJ
    Cancer Cell 2016 Jan 11;29(1):75-89
  • Induction Chemotherapy Followed by Concurrent Full-Dose Gemcitabine and Intensity-Modulated Radiation Therapy for Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma
    Badiyan SN, Olsen JR, Lee AY, Yano M, Menias CO, Khwaja S, Wang-Gillam A, Strasberg SM, Hawkins WG, Linehan DC, Myerson RJ, Parikh PJ
    Am J Clin Oncol 2016 Feb;39(1):1-7
  • A Phase I Study of MK-5108, an Oral Aurora a Kinase Inhibitor, Administered Both as Monotherapy and in Combination With Docetaxel, in Patients With Advanced or Refractory Solid Tumors
    Amin M, Minton SE, LoRusso PM, Krishnamurthi SS, Pickett CA, Lunceford J, Hille D, Mauro D, Stein MN, Wang-Gillam A, Trull L, Lockhart AC
    Invest New Drugs 2016 Feb;34(1):84-95
  • Nanoliposomal Irinotecan With Fluorouracil and Folinic Acid in Metastatic Pancreatic Cancer After Previous Gemcitabine-Based Therapy (NAPOLI-1): A Global, Randomised, Open-Label, Phase 3 Trial
    Wang-Gillam A, Li CP, Bodoky G, Dean A, Shan YS, Jameson G, Macarulla T, Lee KH, Cunningham D, Blanc JF, Hubner RA, Chiu CF, Schwartsmann G, Siveke JT, Braiteh F, Moyo V, Belanger B, Dhindsa N, Bayever E, Von Hoff DD, Chen LT
    NAPOLI-1 Study Group

    Lancet 2016 Feb 6;387(10018):545-57
  • Phase II Trial of Gemcitabine and Tanespimycin (17AAG) in Metastatic Pancreatic Cancer: A Mayo Clinic Phase II Consortium Study
    Pedersen KS, Kim GP, Foster NR, Wang-Gillam A, Erlichman C, McWilliams RR
    Invest New Drugs 2015 Aug;33(4):963-968
  • A Phase II Study of Adjuvant Gemcitabine Plus Docetaxel Followed by Concurrent Chemoradation in Resected Pancreaticobiliary Carcinoma
    Cho M, Wang-Gillam A, Myerson R, Gao F, Strasberg S, Picus J, Sorscher S, Fournier C, Nagaraj G, Parikh P, Suresh R, Linehan D, Tan BR
    HPB (Oxford) 2015 Jul;17(7):587-93
  • Safety and Survival With GVAX Pancreas Prime and Listeria Monocytogenes-Expressing Mesothelin (CRS-207) Boost Vaccines for Metastatic Pancreatic Cancer
    Le DT, Wang-Gillam A, Picozzi V, Greten TF, Crocenzi T, Springett G, Morse M, Zeh H, Cohen D, Fine RL, Onners B, Uram JN, Laheru DA, Lutz ER, Solt S, Murphy AL, Skoble J, Lemmens E, Grous J, Dubensky T Jr, Brockstedt DG, Jaffee EM
    J Clin Oncol 2015 Apr 20;33(12):1325-33
  • Comparison of Implanted Fiducial Markers and Self-Expandable Metallic Stents for Pancreatic Image Guided Radiation Therapy Localization
    Pepin E, Olsen L, Badiyan S, Murad F, Mullady D, Wang-Gillam A, Linehan D, Parikh P, Olsen J
    Pract Radiat Oncol 2015 May-Jun;5(3):e193-9
  • Natural History of Preoperative Subcentimeter Pulmonary Nodules in Patients With Resectable Pancreatic Adenocarcinoma: A Retrospective Cohort Study
    Chang ST, Nguyen DC, Raptis C, Menias CO, Zhou G, Wang-Gillam A, Linehan DC, Hawkins WG, Strasberg SM, Fields RC
    Ann Surg 2015 May;261(5):970-5
  • Thymidylate Synthase Genotype-Directed Chemotherapy for Patients With Gastric and Gastroesophageal Junction Cancers
    Goff LW, Thakkar N, Du L, Chan E, Tan BR, Cardin DB, McLeod HL, Berlin JD, Zehnbauer B, Fournier C, Picus J, Wang-Gillam A, Lee W, Lockhart AC
    PLoS One 2014 Sep 18;9(9):e107424
  • Phase I Dose-Escalation Study of Cabazitaxel Administered in Combination With Cisplatin in Patients With Advanced Solid Tumors
    Lockhart AC, Sundaram S, Sarantopoulos J, Mita MM, Wang-Gillam A, Moseley JL, Barber SL, Lane AR, Wack C, Kassalow L, Dedieu JF, Mita AC
    Invest New Drugs 2014 Dec;32(6):1236-45
  • CSF1/CSF1R Blockade Reprograms Tumor-Infiltrating Macrophages and Improves Response to T-Cell Checkpoint Immunotherapy in Pancreatic Cancer Models
    Zhu Y, Knolhoff BL, Meyer MA, Nywening TM, West BL, Luo J, Wang-Gillam A, Goedegebuure SP, Linehan DC, DeNardo DG
    Cancer Res 2014 Sep 15;74(18):5057-69
  • A Phase I Study of Pegylated Liposomal Doxorubicin and Temsirolimus in Patients With Refractory Solid Malignancies
    Wang-Gillam A, Thakkar N, Lockhart AC, Williams K, Baggstrom M, Naughton M, Suresh R, Ma C, Tan B, Lee W, Jiang X, Mwandoro T, Trull L, Belanger S, Creekmore AN, Gao F, Fracasso PM, Picus J
    Cancer Chemother Pharmacol 2014 Aug;74(2):419-26
  • Tumor-Induced STAT3 Activation in Monocytic Myeloid-Derived Suppressor Cells Enhances Stemness and Mesenchymal Properties in Human Pancreatic Cancer
    Panni RZ, Sanford DE, Belt BA, Mitchem JB, Worley LA, Goetz BD, Mukherjee P, Wang-Gillam A, Link DC, DeNardo DG, Goedegebuure SP, Linehan DC
    Cancer Immunol Immunother 2014 May;63(5):513-28
  • Five Fractions of Radiation Therapy Followed by 4 Cycles of FOLFOX Chemotherapy as Preoperative Treatment for Rectal Cancer
    Myerson RJ, Tan B, Hunt S, Olsen J, Birnbaum E, Fleshman J, Gao F, Hall L, Kodner I, Lockhart AC, Mutch M, Naughton M, Picus J, Rigden C, Safar B, Sorscher S, Suresh R, Wang-Gillam A, Parikh P
    Int J Radiat Oncol Biol Phys 2014 Mar 15;88(4):829-36
  • Supportive Care Considerations During Concurrent Chemoradiotherapy for Pancreatic Adenocarcinoma: Lessons Learned From Clinical Experience
    Wang-Gillam A, Abrams RA, Posner MC, Pisters PW, Picozzi VJ
    Am J Clin Oncol 2013 Dec;36(6):637-43
  • Changing the Way We Do Business: Recommendations to Accelerate Biomarker Development in Pancreatic Cancer
    Tempero MA, Klimstra D, Berlin J, Hollingsworth T, Kim P, Merchant N, Moore M, Pleskow D, Wang-Gillam A, Lowy AM
    Clin Cancer Res 2013 Feb 1;19(3):538-540
  • Vitamin D Deficiency and Prognostics Among Patients With Pancreatic Adenocarcinoma
    Cho M, Peddi PF, Ding K, Chen L, Thomas D, Wang J, Lockhart AC, Tan B, Wang-Gillam A
    J Transl Med 2013 Sep 8;11:206
  • Synergistic Effects of Concurrent Blockade of PI3K and MEK Pathways in Pancreatic Cancer Preclinical Models
    Zhong H, Sanchez C, Spitrzer D, Plambeck-Suess S, Gibbs J, Hawkins WG, Denardo D, Gao F, Pufahl RA, Lockhart AC, Xu M, Linehan D, Weber J, Wang-Gillam A
    PLoS One 2013 Oct 9;8(10):e77243
  • A Study of Zoledronic Acid as Neo-Adjuvant, Perioperative Therapy in Patients With Resectable Pancreatic Ductal Adenocarcinoma
    Sanford DE, Porembka MR, Panni RZ, Mitchem JB, Belt BA, Plambeck-Suess SM, Lin G, Denardo DG, Fields RC, Hawkins WG, Strasberg SM, Lockhart AC, Wang-Gillam A, Goedegebuure SP, Linehan DC
    J Cancer Ther 2013 May;4(3):797-803
  • Nab-Paclitaxel Monotherapy in Refractory Pancreatic Adenocarcinoma
    Peddi PF, Cho M, Wang J, Gao F, Wang-Gillam A
    J Gastrointest Oncol 2013 Dec;4(4):370-3
  • Inflammatory Monocyte Mobilization Decreases Patient Survival in Pancreatic Cancer: A Role for Targeting the CCL2/CCR2 Axis
    Sanford DE, Belt BA, Panni RZ, Mayer A, Deshpande AD, Carpenter D, Mitchem JB, Plambeck-Suess SM, Worley LA, Goetz BD, Wang-Gillam A, Eberlein TJ, Denardo DG, Goedegebuure SP, Linehan DC
    Clin Cancer Res 2013 Jul 1;19(13):3404-15
  • Targeting Tumor-Infiltrating Macrophages Decreases Tumor-Initiating Cells, Relieves Immunosuppression, and Improves Chemotherapeutic Responses
    Mitchem JB, Brennan DJ, Knolhoff BL, Belt BA, Zhu Y, Sanford DE, Belaygorod L, Carpenter D, Collins L, Piwnica-Worms D, Hewitt S, Udupi GM, Gallagher WM, Wegner C, West BL, Wang-Gillam A, Goedegebuure P, Linehan DC, DeNardo DG
    Cancer Res 2013 Feb 1;73(3):1128-1141
  • A Phase I Study of IMP321 and Gemcitabine as the Front-Line Therapy in Patients With Advanced Pancreatic Adenocarcinoma
    Wang-Gillam A, Plambeck-Suess S, Goedegebuure P, Simon PO, Mitchem JB, Hornick JR, Sorscher S, Picus J, Suresh R, Lockhart AC, Tan B, Hawkins WG
    Invest New Drugs 2013 Jun;31(3):707-13
  • Multi-Institutional Experience With FOLFIRINOX in Pancreatic Adenocarcinoma
    Peddi PF, Lubner S, McWilliams R, Tan BR, Picus J, Sorscher SM, Suresh R, Lockhart AC, Wang J, Menias C, Gao F, Linehan D, Wang-Gillam A
    JOP 2012 Sep 10;13(5):497-501
  • A Phase I Dose Escalation Study of TTI-237 in Patients With Advanced Malignant Solid Tumors
    Wang-Gillam A, Arnold SM, Bukowski RM, Rothenberg ML, Cooper W, Wang KK, Gauthier E, Lockhart AC
    Invest New Drugs 2012 Feb;30(1):266-72
  • A Phase I Study of Subcutaneously Administered Aflibercept (VEGF Trap) in a New Formulation in Patients With Advanced Solid Tumors
    Wang-Gillam A, Tew WP, Rothenberg ML, Dupont J, Cooper W, Sternas L, Buzenet G, Sosman JA, Spriggs DR, Lockhart AC
    Invest New Drugs 2012 Oct;30(5):1958-61
  • Influence of Obesity and Other Risk Factors on Survival Outcomes in Patients Undergoing Pancreaticoduodenectomy for Pancreatic Cancer
    Dandona M, Linehan D, Hawkins W, Strasberg S, Gao F, Wang-Gillam A
    Pancreas 2011 Aug;40(6):931-7
  • A Survey of Internet Utilization Among Patients With Cancer
    Castleton K, Fong T, Wang-Gillam A, Waqar MA, Jeffe DB, Kehlenbrink L, Gao F, Govindan R
    Support Care Cancer 2011 Aug;19(8):1183-90
  • Time to Activate Lung Cancer Clinical Trials and Patient Enrollment: A Representative Comparison Study Between Two Academic Centers Across the Atlantic
    Wang-Gillam A, Williams K, Novello S, Gao F, Scagliotti GV, Govindan R
    J Clin Oncol 2010 Aug 20;28(24):3803-7
  • Re: ABO Blood Group and the Risk of Pancreatic Cancer
    Dandona M, Gao F, Linehan DC, Wang-Gillam A
    J Natl Cancer Inst 2010 Jan 20;102(2):135-7
  • Evaluation of Vitamin D Deficiency in Breast Cancer Patients on Bisphosphonates
    Wang-Gillam A, Miles DA, Hutchins LF
    Oncologist 2008 Jul;13(7):821-7
  • Experiences of Institutional Review Board (IRB) and Protocol Review and Monitoring Committee (PRMC) Rotations in Hematology/Oncology Training
    Wang-Gillam A, Valentine J, Sherman AC, Mehta P
    J Cancer Educ 2008 Summer;23(2):71-3
  • Anti-Tumor Effect of Doxycycline on Glioblastoma Cells
    Wang-Gillam A, Siegle E, Mayes D, Hutchins L, Zhou YH
    J Cancer Mol 2007;3(5):147-153
  • Acute Splenic Sequestration Crisis Resembling Sepsis in an Adult With Hemoglobin SC Disease
    Wang-Gillam A, Lee RS, Hsi ED, Brotman DJ
    South Med J 2004 Apr;97(4):413-5
  • Identification and Modification of the Uridine-Binding Site of the UDP-GalNAc (GlcNAc) Pyrophosphorylase
    Wang-Gillam A, Pastuszak I, Stewart M, Drake RR, Elbein AD
    J Biol Chem 2000 Jan 14;275(2):1433-8
  • A 17-Amino Acid Insert Changes UDP-N-Acetylhexosamine Pyrophosphorylase Specificity From UDP-GalNAc to UDP-GlcNAc
    Wang-Gillam A, Pastuszak I, Elbein AD
    J Biol Chem 1998 Oct 16;273(42):27055-7

Invited Publications

  • Pancreatic Cancer
    Wang-Gillam A
    In: The Washington Manual of Oncology, 4th Edition (Morgensztern D, Ghobadi A, Govindan R, Editors), Wolters Kluwer, Philadelphia, 2022
  • Trends in Neoadjuvant Approaches in Pancreatic Cancer
    Du L, Wang-Gillam A
    J Natl Compr Canc Netw 2017 Aug;15(8):1070-1077
  • Promising Therapeutics of Gastrointestinal Cancers in Clinical Trials
    Du L, Che Z, Wang-Gillam A
    J Gastrointest Oncol 2017 Jun;8(3):524-533
  • Entering the Molecular Era of Gastrointestinal Oncology: Current Updates and Challenges
    Wang-Gillam A, Lim KH
    J Gastrointest Oncol 2017 Jun;8(3):377-378
  • Nanoliposomal Irinotecan Plus Fluorouracil and Folinic Acid: A New Treatment Option in Metastatic Pancreatic Cancer
    Saif Ur Rehman S, Lim K, Wang-Gillam A
    Expert Rev Anticancer Ther 2016 May;16(5):485-492
  • Targeting RAS-Mutant Cancers: Is ERK the Key?
    Ryan MB, Der CJ, Wang-Gillam A, Cox AD
    Trends Cancer 2015 Nov 1;1(3):183-198
  • Perioperative Therapy for Surgically Resectable Pancreatic Adenocarcinoma
    Du L, DeFoe M, Ruzinova MB, Olsen JR, Wang-Gillam A
    Hematol Oncol Clin North Am 2015 Aug;29(4):717-726
  • Paving the Road to Clinical Trial Participation: Removing Road Blocks and Directing Patients Toward Novel Therapies
    Wang-Gillam A, Williams K
    J Natl Compr Canc Netw 2015 Jan;13(1):118-20
  • Ras Genes and Cancer
    Hayes T, Stratford K, Wang-Gillam A, Der C
    In: Wittinghofer A (ed): Ras Superfamily Small G Proteins: Biology and Mechanisms. Springer, 2014
  • Pancreatic Cancer
    Wang-Gillam A
    In: Washington Manual of Oncology, 4th edition. Lippincott Williams & Wilkins, Philadelphia, PA
  • Neoadjuvant Therapy of Pancreatic Cancer: The Emerging Paradigm?
    Lim KH, Chung E, Khan A, Cao D, Linehan D, Ben-Josef E, Wang-Gillam A
    Oncologist 2012;17(2):192-200
  • Successful Resection After Neoadjuvant Therapy in Pancreatic Adenocarcinoma
    Peddi PF, Wang-Gillam A
    J Natl Compr Canc Netw 2012 Nov 1;10(11):1330-4
  • Myeloid-Derived Suppressor Cells: General Characteristics and Relevance to Clinical Management of Pancreatic Cancer
    Goedegebuure P, Mitchem JB, Porembka MR, Tan MC, Belt BA, Wang-Gillam A, Gillanders WE, Hawkins WG, Linehan DC
    Curr Cancer Drug Targets 2011 Jul 1;11(6):734-751
  • Current Treatments for Metastatic Colon Cancer
    Wang-Gillam A, Lockhart C, Picus J
    In: Metastasis. Lippincott Williams & Wilkins, 2011
  • Peritoneal Carcinomatosis
    Tran D, Wang-Gillam A
    In: Govindan R (ed). DeVita, Hellman, and Rosenberg's Cancer: Principles and Practice of Oncology Review, 2nd ed. Philadelphia: Lippincott Williams & Wilkins, 2009
  • Hypernatremia. A 77 Year Old Man With Altered Mental Status
    Wang-Gillam A, Hix J, Nurko S
    In: Cleveland Clinic Vignette Book. Lippincott Williams & Wilkins. 2003;231-234